Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)

Mov Disord. 2002 Sep;17(5):1098-100. doi: 10.1002/mds.10209.

Abstract

We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Blepharospasm / drug therapy
  • Blinking / drug effects*
  • Botulinum Toxins, Type A / pharmacology*
  • Botulinum Toxins, Type A / therapeutic use*
  • Female
  • Humans
  • Middle Aged
  • Treatment Outcome

Substances

  • Botulinum Toxins, Type A